Verition Fund Management
FULC icon

Verition Fund Management’s Fulcrum Therapeutics FULC Stock Holding History

Verition Fund Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-74,691
Closed -$845K – 2752
2025
Q4 		$845K Buy
+74,691
New +$760K ﹤0.01% 2288
2025
Q2 		– Sell
-65,388
Closed -$188K – 3711
2025
Q1 		$188K Sell
65,388
-1,655
-2% -$6.08K ﹤0.01% 3060
2024
Q4 		$315K Buy
67,043
+29,400
+78% +$108K ﹤0.01% 2757
2024
Q3 		$134K Buy
+37,643
New +$279K ﹤0.01% 2959
2023
Q4 		– Sell
-19,212
Closed -$85.3K – 2448
2023
Q3 		$85.3K Sell
19,212
-40,337
-68% -$176K ﹤0.01% 2135
2023
Q2 		$197K Buy
59,549
+47,777
+406% +$140K ﹤0.01% 1865
2023
Q1 		$33.5K Buy
+11,772
New +$105K ﹤0.01% 1982
2021
Q4 		– Sell
-20,000
Closed -$564K – 2642
2021
Q3 		$564K Buy
+20,000
New +$379K ﹤0.01% 1177

Other funds holding FULC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $935M AUM 298.58% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Verition Fund Management's FULC Position: Q1 2026 in Review

Verition Fund Management sold out of Fulcrum Therapeutics (FULC) in Q1 2026, closing a stake of 74,691 shares — an estimated $845K sold.

Verition Fund Management first reported a position in FULC in Q3 2021 and held it in 8 quarters. The position peaked at $845K in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Verition Fund Management reported no remaining Fulcrum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 74,691 Fulcrum Therapeutics shares in Q1 2026, an estimated $845K.
  • Verition Fund Management first reported a position in Fulcrum Therapeutics in Q3 2021 and held it in 8 quarters.
  • Verition Fund Management's Fulcrum Therapeutics position peaked at $845K in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.